Share: Facebook Twitter LinkedIn
Activity Provided By:

Physicians’ Education Resource®, LLC.

Putting the Patient First: Individualized Strategies for the Treatment and Management of von Willebrand Disease

Access Activity

Overview / Abstract:

Target Audience

This educational program is directed toward hematologists. Primary care physicians, nurse practitioners, physician assistants, and other health care professionals involved in the treatment of patients with VWD are also invited to participate.

Activity Overview

This online, on-demand virtual symposium brings together renowned experts with experience providing frontline care to patients with von Willebrand disease (VWD). In this educational program, these experts discuss the pathophysiology and clinical picture for the various VWD phenotypes; share insights on the application of the recently released 2021 consensus guidelines for VWD management; provide practical advice for handling challenging cases; and forecast future developments.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

Discuss the genotypic and phenotypic presentation of VWD based on pathophysiology
Evaluate current treatment options for VWD
Develop management plans for patients with VWD
Apply shared decision-making principles to individualize treatment plans for patients with VWD based on presentation


Apr 20, 2022


Physician CME



Credits / Hours

1.0 AMA PRA Category 1 Credit(s)™



Presenters / Authors / Faculty


Jonathan C. Roberts, MD
Associate Medical Director
Associate Research Director
Bleeding & Clotting Disorders Institute
Assistant Professor of Pediatrics
University of Illinois College of Medicine
Peoria, IL

Robert F. Sidonio, Jr., MD, MSc
Pediatric Hematologist/Oncologist
Medical Director of Hemophilia,
Aflac Cancer & Blood Disorders Center
Children’s Healthcare of Atlanta
Associate Professor of Pediatrics,
Emory University School of Medicine
Atlanta, GA

Angela C. Weyand
Assistant Professor of Pediatrics
Division of Hematology and Oncology
University of Michigan Medical School
Ann Arbor, MI

Sponsors / Supporters / Grant Providers

Takeda Pharmaceuticals USA, Inc.

Keywords / Search Terms

Relias LLC Relias LLC., FreeCME., von Willebrand Disease Free CE CME

Access Activity

CORE Higher Education Group,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps.CORE Higher Education Group,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the Terms of Service. Site Map